Sep 23, 2019
Boehringer Ingelheim and Inflammasome Therapeutics Inc. have announced that they have entered into a definitive a co-development and license agreement to develop therapies for the patients with retinal diseases.The deal is about jointly developing three novel therapies for retinal diseases with the help of Inflamma...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper